Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

You may be eligible if

• Relapsed or progressive low-grade/follicular NHL who are candidates for rituximab therapy
• Patients who were on other therapy including CHOP or radiation
• Previous therapy must have concluded 30 days prior to enrollment
• Demonstrable CD20-positive tumor population in lymph nodes or bone marrow